HDAC9 Inhibits Osteoclastogenesis via Mutual Suppression of PPARγ/RANKL Signaling
Molecular Endocrinology · 01.05.2015 · 29 (5) · 730-738
DOI: 10.1210/me.2014-1365 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Endocrinology, erschienen am 01.05.2015. Verfasst von Zixue Jin und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, University of Texas Southwestern Medical Center, Dallas, Texas 75390. Die Arbeit wurde bisher 63-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS.
Abstract (Originalsprache)
Recent studies suggest that the class II histone deacetylase (HDAC)9 plays important roles in physiology such as metabolism and immunity. Here, we report that HDAC9 also controls bone turnover by suppressing osteoclast differentiation and bone resorption. HDAC9 expression is down-regulated during osteoclastogenesis. Ex vivo osteoclast differentiation is accelerated by HDAC9 deletion but diminished by HDAC9 overexpression. HDAC9 knockout mice exhibit elevated bone resorption and lower bone mass. Bone marrow transplantation reveal that the osteoclastogenic defects are intrinsic to the hematopoietic lineage, because the excessive bone resorption phenotype can be conferred in wild-type (WT) mice receiving HDAC9-null bone marrow, and rescued in HDAC9-null mice receiving WT bone marrow. Mechanistically, HDAC9 forms a negative regulatory loop with peroxisome proliferator-activated receptor gamma (PPARg) and receptor activator of nuclear factor kappa-B ligand (RANKL) signaling. On one hand, PPARγ and nuclear factor κB suppress HDAC9 expression, on the other hand, HDAC9 inhibits PPARγ activity in synergy with silencing mediator of retinoic acid and thyroid hormone receptors (SMRT)/NCoR corepressors. These findings identify HDAC9 as a novel, important and physiologically relevant modulator of bone remodeling and skeletal homeostasis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, University of Texas Southwestern Medical Center, Dallas, Texas 75390.
Förderung
- NIDDK NIH HHS
Zitieren
APA
Jin, Z., Wei, W., Huynh, H., & Wan, Y. (2015). HDAC9 Inhibits Osteoclastogenesis via Mutual Suppression of PPARγ/RANKL Signaling. Molecular Endocrinology, 29(5), 730-738. https://doi.org/10.1210/me.2014-1365
Vancouver
Jin Z, Wei W, Huynh H, Wan Y. HDAC9 Inhibits Osteoclastogenesis via Mutual Suppression of PPARγ/RANKL Signaling. Molecular Endocrinology. 2015;29(5):730-738. doi:10.1210/me.2014-1365
BibTeX
@article{Jin2015,
author = {Jin, Zixue and Wei, Wei and Huynh, HoangDinh and Wan, Yihong},
title = {HDAC9 Inhibits Osteoclastogenesis via Mutual Suppression of PPARγ/RANKL Signaling},
journal = {Molecular Endocrinology},
year = {2015},
volume = {29},
number = {5},
pages = {730--738},
doi = {10.1210/me.2014-1365}
}
EUVIMED